- The FDA-approved drug buprenorphine is effective in the treatment of opioid use disorder, but limited access to clinics that can prescribe this drug has contributed to only a small fraction of patients receiving the treatment.
- Researchers have suggested that a collaborative care model involving the delegation of the care of opioid use disorder patients by clinicians to pharmacists could improve access to buprenorphine.
- A pilot study conducted as part of a randomized phase 3 clinical trial…
Read the full article here